Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.

abstract：INTRODUCTION:In the treatment of advanced/metastatic head and neck cancer (HNC), resistance to chemotherapy and to anti-EGFR agents remains a major issue, and new molecular drugs are eagerly awaited. Over the last decade, knowledge of the genetic landscape of HNC has rapidly grown. However, no tailored therapeutic inte...

journal_title：Expert opinion on investigational drugs

authors： Bossi P,Alfieri S

更新日期：2016-07-01 00:00:00

abstract：INTRODUCTION:Patients with myelofibrosis (MF) have no effective treatment option after the failure of approved JAK inhibitor (JAKi) therapy. Non-JAK inhibitors (non-JAKi) that target non-canonical molecular pathways are undergoing clinical evaluations to optimize efficacy and/or to reduce hematological toxicity of JAKi...

journal_title：Expert opinion on investigational drugs

authors： Bankar A,Gupta V

更新日期：2020-05-01 00:00:00

abstract：INTRODUCTION:In 2010, about 8.8 million new cases of tuberculosis were recorded and 1.1 million people died of tuberculosis worldwide. Although numbers are in decrease since 2006, tuberculosis still represents a global issue and a major public health threat, due to appearance of multidrug-resistant and extensively drug...

journal_title：Expert opinion on investigational drugs

authors： Engohang-Ndong J

更新日期：2012-12-01 00:00:00

abstract：INTRODUCTION:The highly divergent histological heterogeneities, aggressive invasion and extremely poor response to treatment make glioblastoma (GBM) one of the most lethal and difficult cancers in humans. Among key elements driving its behavior is epidermal growth factor receptor (EGFR), however, neither traditional th...

journal_title：Expert opinion on investigational drugs

authors： Gao Q,Lei T,Ye F

更新日期：2013-08-01 00:00:00

abstract：:Suicide gene therapy is the approach whereby the genetic alteration of a cell renders it susceptible to an otherwise non-toxic prodrug. Suicide gene therapy for solid tumours has progressed rapidly since the concept was originally described: nearly all tumour types have been explored, with some, such as glioma, melano...

journal_title：Expert opinion on investigational drugs

authors： Perry MJ,Todryk SM,Dalgleish AG

更新日期：1999-06-01 00:00:00

abstract：:Transcription factors are proteins that regulate gene transcription and expression. In many cases of acute leukaemia chromosomal aberrations are translocations of transcription factors which change their expression and induce the leukaemic phenotype. These abnormal transcription factors are tumour-specific and can be ...

journal_title：Expert opinion on investigational drugs

authors： Douer D

更新日期：2000-02-01 00:00:00

abstract：BACKGROUND:Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder. It is the R-enantiomer of the compound modafinil. Like modafinil, the mechanism of action for armoda...

journal_title：Expert opinion on investigational drugs

authors： Lankford DA

更新日期：2008-04-01 00:00:00

abstract：:INH-A21 is an experimental human immune globulin for intravenous infusion (IGIV) derived from donors specifically selected for elevated levels of antibodies against the Staphylococcal fibrinogen-binding proteins, serine aspartate dipeptide repeat G and clumping factor A. Phase II results demonstrated that infusions of...

journal_title：Expert opinion on investigational drugs

authors： Bloom BT

更新日期：2006-06-01 00:00:00

abstract：INTRODUCTION:The N-methyl-d-aspartate receptor-ionophore complex plays a key role in learning and memory and has efficacy in animals and humans with affective disorders. GLYX-13 is an N-methyl-d-aspartate receptor (NMDAR) glycine-site functional partial agonist and cognitive enhancer that also shows rapid antidepressan...

journal_title：Expert opinion on investigational drugs

authors： Moskal JR,Burch R,Burgdorf JS,Kroes RA,Stanton PK,Disterhoft JF,Leander JD

更新日期：2014-02-01 00:00:00

abstract：INTRODUCTION:Circadian rhythm is a natural endogenous process occurring roughly every 24 hours. Circadian rhythm dysfunction is involved in diabetic retinopathy (DR) pathogenesis. Interestingly, there are investigational drugs that exhibit potential in the treatment of DR by targeting circadian rhythm dysfunction. ARE...

journal_title：Expert opinion on investigational drugs

authors： Bhatwadekar AD,Rameswara V

更新日期：2020-12-01 00:00:00

abstract：:Gaucher disease (GD) is an inborn error of glycosphingolipid metabolism, associated with multisystemic manifestations resulting from the lysosomal accumulation of an incompletely degraded material (glucosylceramide) within cells of monocyte/macrophage lineage. In the majority of GD patients with non-neurological invol...

journal_title：Expert opinion on investigational drugs

authors： Pastores GM,Barnett NL

更新日期：2003-02-01 00:00:00

abstract：:Numerous studies over the last few years have suggested that modulating the glutamatergic system may be an efficient method to achieve an antidepressant effect. Data suggest that metabotropic glutamate receptors (mGlu receptors), related to long-term, modulatory effects on glutamatergic neurotransmission, may be a goo...

journal_title：Expert opinion on investigational drugs

authors： Palucha A

更新日期：2006-12-01 00:00:00

abstract：:A disintegrin and metalloproteases (ADAMs) are zinc-dependent trans-membrane metalloproteases that shed the extracellular domains of membrane-bound growth factors, cytokines and receptors. Key functions of ADAMs have emerged in ErbB signalling pathways as being sheddases for multiple ErbB ligands. As the ErbB pathway ...

journal_title：Expert opinion on investigational drugs

authors： Zhou BB,Fridman JS,Liu X,Friedman SM,Newton RC,Scherle PA

更新日期：2005-06-01 00:00:00

abstract：:Endothelin (ET) is a pivotal physiological regulator of blood pressure through its effects on blood vessels, heart, lung and kidneys, and the ET system can be overactive in disorders such as pulmonary hypertension, heart failure and renal disease. Such observations stimulated interest among scientists and pharmaceutic...

journal_title：Expert opinion on investigational drugs

authors： Benigni A,Perico N,Remuzzi G

更新日期：2004-11-01 00:00:00

abstract：:Introduction: Advanced melanoma historically had a very poor outcome but targeted therapies and immune checkpoint inhibitors (IC) have changed the course of the disease and made durable responses possible. However, most patients will develop progressive disease, so further strategies to overcome treatment resistance a...

journal_title：Expert opinion on investigational drugs

authors： Boos LA,Leslie I,Larkin J

更新日期：2020-07-01 00:00:00

abstract：INTRODUCTION:Currently, there is no cure available for the hereditary neurodegenerative disease proximal spinal muscular atrophy (SMA), which is the number one genetic killer in early childhood. However, growing knowledge of SMA pathophysiology has opened new avenues for potential therapeutic interventions. AREAS COVE...

journal_title：Expert opinion on investigational drugs

authors： Kaczmarek A,Schneider S,Wirth B,Riessland M

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Sorafenib is an oral multikinase inhibitor with anti-angiogenic and anti-proliferative activity that is indicated for use in hepatocellular and renal cell carcinomas. Sorafenib is being developed in a number of solid tumors, including breast cancer (BC). AREAS COVERED:A series of four randomized, double-b...

journal_title：Expert opinion on investigational drugs

authors： Gradishar WJ

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:The significant proportion of gout patients not reaching serum urate levels below 6.0 mg/dL and the debated pathogenicity of hyperuricemia (HU) itself motivate investigators to develop new drugs to decrease uricemia. AREAS COVERED:This review discusses the drugs considered to be in active development from...

journal_title：Expert opinion on investigational drugs

authors： Pascart T,Richette P

更新日期：2018-05-01 00:00:00

abstract：INTRODUCTION:Axial spondyloarthritis (AxS pA) is a chronic inflammatory disease for which, until recently, there were no valid therapeutic alternatives to TNF-α blocking agents. This unmet clinical need led to explore several therapeutic targets, from proinflammatory cytokines to intracellular signaling systems. The re...

journal_title：Expert opinion on investigational drugs

authors： Clavel G,Boissier MC,Sigaux J,Semerano L

更新日期：2017-07-01 00:00:00

abstract：:Inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) has an established role in the treatment of advanced non-small cell lung cancer. The first-generation EGFR inhibitors erlotinib and gefitinib have been approved for treatment in the second- and third-line setting. Second-generation ...

journal_title：Expert opinion on investigational drugs

authors： Mukherji D,Spicer J

更新日期：2009-03-01 00:00:00

abstract：INTRODUCTION:Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatme...

journal_title：Expert opinion on investigational drugs

authors： Thanarajasingam U,Niewold TB

更新日期：2014-10-01 00:00:00

abstract：BACKGROUND:Age-related macular degeneration is the leading cause of blindness among elderly individuals in industrialized countries. New drugs and advanced concepts for the treatment of dry AMD (dAMD) are needed. A new approach is the application of intravenous infusions of prostaglandin E1. OBJECTIVE:The aim of this ...

journal_title：Expert opinion on investigational drugs

authors： Augustin AJ,Diehm C,Grieger F,Bentz J

更新日期：2013-07-01 00:00:00

abstract：:In most countries the last two decades have seen a very substantial rise in the prevalence of heart failure, and in a majority of patients hypertension is both an antecedent condition and a contributing cause. Heart failure is also a major cause of hospital admissions; its amelioration and, as far as possible, prevent...

journal_title：Expert opinion on investigational drugs

authors： Funder JW

更新日期：2003-12-01 00:00:00

abstract：:There are several reasons to believe that agents that augment cAMP-mediated signalling in cardiac myocytes should have beneficial effects in patients with heart failure. However, clinical trials of first-generation cyclic nucleotide phosphodiesterase (PDE3) inhibitors, which raise cAMP content by blocking its hydrolys...

journal_title：Expert opinion on investigational drugs

authors： Movsesian MA

更新日期：2000-05-01 00:00:00

abstract：INTRODUCTION:Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for...

journal_title：Expert opinion on investigational drugs

authors： Bickston SJ,Snider KR,Kappus MR

更新日期：2012-12-01 00:00:00

abstract：:Innate immune mechanisms respond rapidly to bacterial infection. A key cellular component of the innate immune response is the neutrophil, whose cytoplasmic granules contain a variety of antimicrobial proteins and peptides. Among these is the bactericidal/permeability-increasing protein (BPI), a cationic 55 kDa protei...

journal_title：Expert opinion on investigational drugs

authors： Levy O

更新日期：2002-02-01 00:00:00

abstract：:Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism...

journal_title：Expert opinion on investigational drugs

authors： Wood M,Reavill C

更新日期：2007-06-01 00:00:00

abstract：INTRODUCTION:Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis. However, ruxolitinib, approved in 2011, remains the only one currently available for treatment of myelofibrosis, with man...

journal_title：Expert opinion on investigational drugs

authors： Bose P,Abou Zahr A,Verstovsek S

更新日期：2017-06-01 00:00:00

abstract：BACKGROUND:Histone deacetylases (HDACs), which target histones as well as non-histone proteins as substrates, have the potential to regulate aberrant gene expression and restore normal growth control in malignancies. OBJECTIVE:This review provides an updated summary of preclinical and clinical experience with the oral...

journal_title：Expert opinion on investigational drugs

authors： Le Tourneau C,Siu LL

更新日期：2008-08-01 00:00:00

abstract：:Introduction: Molecular analyzes including molecular descriptor/phenotype interactions have led to better characterization of epithelial ovarian cancer patients, including a definition of a BRCA wild-type (BRCAwt) phenotype. Understanding how and when to use agents targeted against dependent BRCAwt pathways or other m...

journal_title：Expert opinion on investigational drugs

authors： Ivy SP,Kunos CA,Arnaldez FI,Kohn EC

更新日期：2019-09-01 00:00:00